Get startedLog in
    Picture of Contineum Therapeutics logo

    CTNM — Contineum Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapNeutral
    All News

    Brief: Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

    Picture of Contineum Therapeutics logoContineum Therapeutics
    08/01/2025 21:12
    Jan 8 (Reuters) - Contineum Therapeutics Inc  CTNM.O :
    * CONTINEUM THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2
PIPE-307
VISTA TRIAL FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE
SCLEROSIS (RRMS)

Source text:  ID:nBw3JfXf7a 
Further company coverage:  CTNM.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Contineum Therapeutics

    See all news